These include IL23A (targeted by ustekinumab, guselkumab, risankizumab, tildrakizumab, and mirikizumab in psoriasis), IL4 and IL13 (receptor targeted by dupilumab in atopic dermatitis), and TNFRSF1A which encodes TNFR1 (anti-TNF agents include infliximab, adalimumab, etanercept, golimumab, and certolizumab in psoriasis). This evidence concerns the gene IL4 and psoriasis.